File(s) not publicly available
Nonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivo
journal contribution
posted on 2023-06-08, 13:36 authored by Tiziana Mennini, Massimiliano De Paola, Paolo Bigini, Cristina Mastrotto, Elena Fumagalli, Sara Barbera, Manuela MengozziManuela Mengozzi, othersChronic treatment with asialo erythropoietin (ASIALO-EPO) or carbamylated erythropoietin (CEPO) improved motor behavior and reduced motoneuron loss and astrocyte and microglia activation in the cervical spinal cord of wobbler mice, an animal model of amyotrophic lateral sclerosis, but had no effect on hematocrit values. ASIALO-EPO and CEPO, like the parent compound EPO, protected primary motoneuron cultures from kainate-induced death in vitro. Both EPO receptor and the common CD131 beta chain were expressed in cultured motoneurons and in the anterior horn of wobbler mice spinal cord. Our results strongly support a role for the common beta chain CD131 in the protective effect of EPO derivatives on motoneuron degeneration. Thus CEPO, which does not bind to the classical homodimeric EPO receptor and is devoid of hematopoietic activity, could be effective in chronic treatment aimed at reducing motoneuron degeneration
History
Publication status
- Published
Journal
Molecular MedicineISSN
1076-1551Publisher
Feinstein Institute for Medical ResearchExternal DOI
Issue
7-8Volume
12Page range
153-60Department affiliated with
- Clinical and Experimental Medicine Publications
Full text available
- No
Peer reviewed?
- Yes